bax, but not bcl-2, influences the prognosis of human pancreatic cancer

H. Friess, Z. Lu, H. U. Graber, A. Zimmermann, G. Adler, Murray Korc, R. M. Schmid, M. W. Büchler

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Background-bcl-2 and bax belong to the bcl-2-related gene family, which marks a new class of genes that influence apoptosis. The bcl-2 oncogene acts as a broad antiapoptotic factor and extends both normal and tumour cell survival. In contrast, the bax gene is a promoter of apoptosis. Aims-To analyse the expression of bcl-2 and bax in pancreatic cancer and correlate the results with clinical parameters. Patients-Pancreatic cancer tissue samples were obtained from 28 female and 32 male patients (median age 63, range 43-79 years) having surgery for pancreatic cancer. Normal pancreatic tissues obtained from 18 previously healthy organ donors served as controls. Methods-The levels of bcl-2 and bax mRNA expression were analysed by northern blot and the exact site of mRNA transcription was determined by in situ hybridisation. The presence of the corresponding proteins was determined by immunohistochemistry. Results-Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-2 mRNA was overexpressed in 30% and bax mRNA in 61% of the pancreatic cancer samples. Concomitant overexpression of bcl-2 and bax was present in 26% of the cancer samples. Pancreatic adenocarcinomas exhibited 3.7-fold and 5.4-fold increases (p

Original languageEnglish (US)
Pages (from-to)414-421
Number of pages8
JournalGut
Volume43
Issue number3
StatePublished - 1998
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Messenger RNA
Northern Blotting
Apoptosis
bcl-2 Genes
Oncogenes
Genes
In Situ Hybridization
Pancreas
Neoplasms
Cell Survival
Adenocarcinoma
Immunohistochemistry
Tissue Donors
Proteins

Keywords

  • Apoptosis
  • Immunohistochemistry
  • In situ hybridisation
  • Northern blot analysis
  • Pancreatic cancer

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Friess, H., Lu, Z., Graber, H. U., Zimmermann, A., Adler, G., Korc, M., ... Büchler, M. W. (1998). bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut, 43(3), 414-421.

bax, but not bcl-2, influences the prognosis of human pancreatic cancer. / Friess, H.; Lu, Z.; Graber, H. U.; Zimmermann, A.; Adler, G.; Korc, Murray; Schmid, R. M.; Büchler, M. W.

In: Gut, Vol. 43, No. 3, 1998, p. 414-421.

Research output: Contribution to journalArticle

Friess, H, Lu, Z, Graber, HU, Zimmermann, A, Adler, G, Korc, M, Schmid, RM & Büchler, MW 1998, 'bax, but not bcl-2, influences the prognosis of human pancreatic cancer', Gut, vol. 43, no. 3, pp. 414-421.
Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M et al. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 1998;43(3):414-421.
Friess, H. ; Lu, Z. ; Graber, H. U. ; Zimmermann, A. ; Adler, G. ; Korc, Murray ; Schmid, R. M. ; Büchler, M. W. / bax, but not bcl-2, influences the prognosis of human pancreatic cancer. In: Gut. 1998 ; Vol. 43, No. 3. pp. 414-421.
@article{b276139d963c4661aeeea56b40c47a52,
title = "bax, but not bcl-2, influences the prognosis of human pancreatic cancer",
abstract = "Background-bcl-2 and bax belong to the bcl-2-related gene family, which marks a new class of genes that influence apoptosis. The bcl-2 oncogene acts as a broad antiapoptotic factor and extends both normal and tumour cell survival. In contrast, the bax gene is a promoter of apoptosis. Aims-To analyse the expression of bcl-2 and bax in pancreatic cancer and correlate the results with clinical parameters. Patients-Pancreatic cancer tissue samples were obtained from 28 female and 32 male patients (median age 63, range 43-79 years) having surgery for pancreatic cancer. Normal pancreatic tissues obtained from 18 previously healthy organ donors served as controls. Methods-The levels of bcl-2 and bax mRNA expression were analysed by northern blot and the exact site of mRNA transcription was determined by in situ hybridisation. The presence of the corresponding proteins was determined by immunohistochemistry. Results-Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-2 mRNA was overexpressed in 30{\%} and bax mRNA in 61{\%} of the pancreatic cancer samples. Concomitant overexpression of bcl-2 and bax was present in 26{\%} of the cancer samples. Pancreatic adenocarcinomas exhibited 3.7-fold and 5.4-fold increases (p",
keywords = "Apoptosis, Immunohistochemistry, In situ hybridisation, Northern blot analysis, Pancreatic cancer",
author = "H. Friess and Z. Lu and Graber, {H. U.} and A. Zimmermann and G. Adler and Murray Korc and Schmid, {R. M.} and B{\"u}chler, {M. W.}",
year = "1998",
language = "English (US)",
volume = "43",
pages = "414--421",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - bax, but not bcl-2, influences the prognosis of human pancreatic cancer

AU - Friess, H.

AU - Lu, Z.

AU - Graber, H. U.

AU - Zimmermann, A.

AU - Adler, G.

AU - Korc, Murray

AU - Schmid, R. M.

AU - Büchler, M. W.

PY - 1998

Y1 - 1998

N2 - Background-bcl-2 and bax belong to the bcl-2-related gene family, which marks a new class of genes that influence apoptosis. The bcl-2 oncogene acts as a broad antiapoptotic factor and extends both normal and tumour cell survival. In contrast, the bax gene is a promoter of apoptosis. Aims-To analyse the expression of bcl-2 and bax in pancreatic cancer and correlate the results with clinical parameters. Patients-Pancreatic cancer tissue samples were obtained from 28 female and 32 male patients (median age 63, range 43-79 years) having surgery for pancreatic cancer. Normal pancreatic tissues obtained from 18 previously healthy organ donors served as controls. Methods-The levels of bcl-2 and bax mRNA expression were analysed by northern blot and the exact site of mRNA transcription was determined by in situ hybridisation. The presence of the corresponding proteins was determined by immunohistochemistry. Results-Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-2 mRNA was overexpressed in 30% and bax mRNA in 61% of the pancreatic cancer samples. Concomitant overexpression of bcl-2 and bax was present in 26% of the cancer samples. Pancreatic adenocarcinomas exhibited 3.7-fold and 5.4-fold increases (p

AB - Background-bcl-2 and bax belong to the bcl-2-related gene family, which marks a new class of genes that influence apoptosis. The bcl-2 oncogene acts as a broad antiapoptotic factor and extends both normal and tumour cell survival. In contrast, the bax gene is a promoter of apoptosis. Aims-To analyse the expression of bcl-2 and bax in pancreatic cancer and correlate the results with clinical parameters. Patients-Pancreatic cancer tissue samples were obtained from 28 female and 32 male patients (median age 63, range 43-79 years) having surgery for pancreatic cancer. Normal pancreatic tissues obtained from 18 previously healthy organ donors served as controls. Methods-The levels of bcl-2 and bax mRNA expression were analysed by northern blot and the exact site of mRNA transcription was determined by in situ hybridisation. The presence of the corresponding proteins was determined by immunohistochemistry. Results-Northern blot analysis indicated that, in comparison with the normal pancreas, bcl-2 mRNA was overexpressed in 30% and bax mRNA in 61% of the pancreatic cancer samples. Concomitant overexpression of bcl-2 and bax was present in 26% of the cancer samples. Pancreatic adenocarcinomas exhibited 3.7-fold and 5.4-fold increases (p

KW - Apoptosis

KW - Immunohistochemistry

KW - In situ hybridisation

KW - Northern blot analysis

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0031715838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031715838&partnerID=8YFLogxK

M3 - Article

C2 - 9863489

AN - SCOPUS:0031715838

VL - 43

SP - 414

EP - 421

JO - Gut

JF - Gut

SN - 0017-5749

IS - 3

ER -